Bevacizumab with chemotherapy in patients with KRAS wild-type
metastatic colorectal cancer: Czech registry data

J 2015

Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data

KUBÁČKOVÁ, Kateřina; Zbyněk BORTLÍČEK; Tomáš PIKUS; Zdeněk LINKE; Petra POKORNÁ et al.

Základní údaje

Originální název

Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data

Autoři

KUBÁČKOVÁ, Kateřina; Zbyněk BORTLÍČEK; Tomáš PIKUS; Zdeněk LINKE; Petra POKORNÁ; Rostislav VYZULA a Jana PRAUSOVÁ

Vydání

Future Oncology, LONDON, Future Medicine, 2015, 1479-6694

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.129

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/15:00082994

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

bevacizumab; chemotherapy; colorectal cancer; KRAS

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 28. 5. 2015 15:34, Soňa Böhmová

Anotace

V originále

Aim: This retrospective analysis investigated the effectiveness of combination therapy with bevacizumab and chemotherapy in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer. Patients & methods: Patients with KRAS wildtype metastatic colorectal cancer in the CORECT registry who initiated treatment with bevacizumab between 2008 and 2012 were enrolled. Overall survival and progression-free survival were the main effectiveness end points. Results: A total of 981 patients were enrolled. Median progression-free survival was 11.3 months (95% CI: 10.7-11.8) and median overall survival was 28.4 months (95% CI: 26.2-30.6). The most common adverse events were thromboembolic disease (4%) and hypertension (3.5%). Conclusion: This retrospective analysis shows the effectiveness of bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer.

Citovat

KUBÁČKOVÁ, Kateřina; Zbyněk BORTLÍČEK; Tomáš PIKUS; Zdeněk LINKE; Petra POKORNÁ; Rostislav VYZULA a Jana PRAUSOVÁ. Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data. Future Oncology. LONDON: Future Medicine, 2015, roč. 11, č. 2, s. 225-232. ISSN 1479-6694. Dostupné z: https://doi.org/10.2217/FON.14.240.

@article{1300160,
   author = {Kubáčková, Kateřina and Bortlíček, Zbyněk and Pikus, Tomáš and Linke, Zdeněk and Pokorná, Petra and Vyzula, Rostislav and Prausová, Jana},
   article_location = {LONDON},
   article_number = {2},
   doi = {https://doi.org/10.2217/FON.14.240},
   keywords = {bevacizumab; chemotherapy; colorectal cancer; KRAS},
   language = {eng},
   issn = {1479-6694},
   journal = {Future Oncology},
   title = {Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data},
   volume = {11},
   year = {2015}
}

TY  - JOUR
ID  - 1300160
AU  - Kubáčková, Kateřina - Bortlíček, Zbyněk - Pikus, Tomáš - Linke, Zdeněk - Pokorná, Petra - Vyzula, Rostislav - Prausová, Jana
PY  - 2015
TI  - Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data
JF  - Future Oncology
VL  - 11
IS  - 2
SP  - 225-232
EP  - 225-232
PB  - Future Medicine
SN  - 14796694
KW  - bevacizumab
KW  - chemotherapy
KW  - colorectal cancer
KW  - KRAS
N2  - Aim: This retrospective analysis investigated the effectiveness of combination therapy with bevacizumab and chemotherapy in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer. Patients & methods: Patients with KRAS wildtype metastatic colorectal cancer in the CORECT registry who initiated treatment with bevacizumab between 2008 and 2012 were enrolled. Overall survival and progression-free survival were the main effectiveness end points. Results: A total of 981 patients were enrolled. Median progression-free survival was 11.3 months (95% CI: 10.7-11.8) and median overall survival was 28.4 months (95% CI: 26.2-30.6). The most common adverse events were thromboembolic disease (4%) and hypertension (3.5%). Conclusion: This retrospective analysis shows the effectiveness of bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer.
ER  -

KUBÁČKOVÁ, Kateřina; Zbyněk BORTLÍČEK; Tomáš PIKUS; Zdeněk LINKE; Petra POKORNÁ; Rostislav VYZULA a Jana PRAUSOVÁ. Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data. \textit{Future Oncology}. LONDON: Future Medicine, 2015, roč.~11, č.~2, s.~225-232. ISSN~1479-6694. Dostupné z: https://doi.org/10.2217/FON.14.240.

Přehled o publikaci